WO2004056843A3 - 10-substituted macrolide antibiotics - Google Patents

10-substituted macrolide antibiotics Download PDF

Info

Publication number
WO2004056843A3
WO2004056843A3 PCT/GB2003/005659 GB0305659W WO2004056843A3 WO 2004056843 A3 WO2004056843 A3 WO 2004056843A3 GB 0305659 W GB0305659 W GB 0305659W WO 2004056843 A3 WO2004056843 A3 WO 2004056843A3
Authority
WO
WIPO (PCT)
Prior art keywords
macrolide antibiotics
substituted macrolide
substituted
macrolides
erythromycin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2003/005659
Other languages
French (fr)
Other versions
WO2004056843A2 (en
Inventor
Kjell Undheim
Soelvi Gunnes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xellia Pharmaceuticals ApS
Original Assignee
Alpharma ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alpharma ApS filed Critical Alpharma ApS
Priority to EP03782698A priority Critical patent/EP1575970A2/en
Priority to CA2509419A priority patent/CA2509419C/en
Priority to US10/539,759 priority patent/US7608596B2/en
Priority to AU2003290339A priority patent/AU2003290339B8/en
Publication of WO2004056843A2 publication Critical patent/WO2004056843A2/en
Publication of WO2004056843A3 publication Critical patent/WO2004056843A3/en
Anticipated expiration legal-status Critical
Priority to US12/569,926 priority patent/US8076301B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

The application provides antibiotic 10-substituted 10-desmethyl macrolides. In a preferred embodiment the macrolides have an erythromycin basic structure according the formula, wherein the variable substituents have the meaning indicated in the description.
PCT/GB2003/005659 2002-12-20 2003-12-22 10-substituted macrolide antibiotics Ceased WO2004056843A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP03782698A EP1575970A2 (en) 2002-12-20 2003-12-22 10-substituted macrolide antibiotics
CA2509419A CA2509419C (en) 2002-12-20 2003-12-22 Macrolides
US10/539,759 US7608596B2 (en) 2002-12-20 2003-12-22 10-substituted macrolide antibiotics
AU2003290339A AU2003290339B8 (en) 2002-12-20 2003-12-22 10-Substituted macrolide antibiotics
US12/569,926 US8076301B2 (en) 2002-12-20 2009-09-30 10-substituted macrolide antibiotics

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200201957 2002-12-20
DK200201957A DK200201957A (en) 2002-12-20 2002-12-20 10-substituted erythromycin ketolides and methods of making

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10/539,759 A-371-Of-International US7608596B2 (en) 2002-12-20 2003-12-22 10-substituted macrolide antibiotics
US12/569,926 Division US8076301B2 (en) 2002-12-20 2009-09-30 10-substituted macrolide antibiotics

Publications (2)

Publication Number Publication Date
WO2004056843A2 WO2004056843A2 (en) 2004-07-08
WO2004056843A3 true WO2004056843A3 (en) 2004-10-21

Family

ID=8161253

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2003/005659 Ceased WO2004056843A2 (en) 2002-12-20 2003-12-22 10-substituted macrolide antibiotics

Country Status (7)

Country Link
US (2) US7608596B2 (en)
EP (3) EP2354147A3 (en)
CN (1) CN1729200A (en)
AU (1) AU2003290339B8 (en)
CA (2) CA2789415C (en)
DK (1) DK200201957A (en)
WO (1) WO2004056843A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201217310D0 (en) 2012-09-27 2012-11-14 C10 Pharma As Compounds
US11261113B2 (en) 2017-08-30 2022-03-01 Ecolab Usa Inc. Molecules having one hydrophobic group and two identical hydrophilic ionic groups and compositions thereof and methods of preparation thereof
CA3110365C (en) 2018-08-29 2023-05-09 Ecolab Usa Inc. Use of multiple charged ionic compounds derived from polyamines for waste water clarification
US11685709B2 (en) 2018-08-29 2023-06-27 Ecolab Usa Inc. Multiple charged ionic compounds derived from polyamines and compositions thereof and use thereof as reverse emulsion breakers in oil and gas operations
US11084974B2 (en) 2018-08-29 2021-08-10 Championx Usa Inc. Use of multiple charged cationic compounds derived from polyamines for clay stabilization in oil and gas operations
CN112601718A (en) * 2018-08-29 2021-04-02 埃科莱布美国股份有限公司 Use of multiply charged cationic compounds derived from primary amines or polyamines for controlling microbial fouling in aqueous systems
US11236040B2 (en) 2018-08-29 2022-02-01 Ecolab Usa Inc. Multiple charged ionic compounds derived from polyamines and compositions thereof and methods of preparation thereof
CN113365498B (en) 2019-01-29 2022-10-25 埃科莱布美国股份有限公司 Use of cationic glycosyl compounds for microbial fouling control in aqueous systems
CA3136427C (en) 2019-04-16 2023-10-24 Ecolab Usa Inc. Use of multiple charged cationic compounds derived from polyamines and compositions thereof for corrosion inhibition in a water system
CN117624172B (en) * 2023-11-29 2024-07-16 山东第一医科大学附属眼科研究所(山东省眼科研究所、山东第一医科大学附属青岛眼科医院) Organic molecular cage, organic molecular cage nano enzyme eye drops and preparation method thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2692579A1 (en) * 1992-06-19 1993-12-24 Roussel Uclaf New picromycin cyclic carbamate derivs. - useful as antibiotics against gram-positive bacteria
WO1998001571A2 (en) * 1996-07-05 1998-01-15 Biotica Technology Limited Erythromycins and process for their preparation
WO1998025942A1 (en) * 1996-12-12 1998-06-18 Hoechst Marion Roussel Novel erythromycin derivatives, method for preparing them and their use as medicine
WO1998051695A2 (en) * 1997-05-16 1998-11-19 Abbott Laboratories Novel polyketide derivatives and recombinant methods for making same
WO2002060912A1 (en) * 2000-12-22 2002-08-08 Enanta Pharmaceuticals, Inc. 14-membered macrolides derived from leucomycins

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4509553B2 (en) 2001-07-03 2010-07-21 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド C12-modified erythromycin macrolide and ketolide having antibacterial activity
US6992069B2 (en) 2002-04-30 2006-01-31 Yu-Gui Gu Tricyclic macrolide antibacterial compounds
EP1501846B1 (en) * 2002-04-30 2009-03-18 Abbott Laboratories Tricyclic macrolide antibacterial compounds

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2692579A1 (en) * 1992-06-19 1993-12-24 Roussel Uclaf New picromycin cyclic carbamate derivs. - useful as antibiotics against gram-positive bacteria
WO1998001571A2 (en) * 1996-07-05 1998-01-15 Biotica Technology Limited Erythromycins and process for their preparation
WO1998025942A1 (en) * 1996-12-12 1998-06-18 Hoechst Marion Roussel Novel erythromycin derivatives, method for preparing them and their use as medicine
WO1998051695A2 (en) * 1997-05-16 1998-11-19 Abbott Laboratories Novel polyketide derivatives and recombinant methods for making same
WO2002060912A1 (en) * 2000-12-22 2002-08-08 Enanta Pharmaceuticals, Inc. 14-membered macrolides derived from leucomycins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHU, D. TW: "Recent developments in 14- and 15-membered macrolides", EXP. OPIN. INVEST. DRUGS, vol. 4, no. 2, 1995, pages 65 - 94, XP002279502 *

Also Published As

Publication number Publication date
CA2509419A1 (en) 2004-07-08
CA2509419C (en) 2013-07-02
EP2371833A3 (en) 2013-07-03
EP2354147A2 (en) 2011-08-10
AU2003290339B8 (en) 2011-02-24
US20060241060A1 (en) 2006-10-26
EP2371833A2 (en) 2011-10-05
DK200201957A (en) 2003-01-20
EP2354147A3 (en) 2013-07-03
CA2789415A1 (en) 2004-07-08
CA2789415C (en) 2014-09-09
EP1575970A2 (en) 2005-09-21
US7608596B2 (en) 2009-10-27
US8076301B2 (en) 2011-12-13
WO2004056843A2 (en) 2004-07-08
AU2003290339B2 (en) 2010-10-28
CN1729200A (en) 2006-02-01
US20100137234A1 (en) 2010-06-03
AU2003290339A1 (en) 2004-07-14

Similar Documents

Publication Publication Date Title
EP1363925B8 (en) Macrolide antibiotics
AU2003301087A1 (en) Flex-circuit-based high speed transmission line
DE69919769D1 (en) 3,6-ketal macrolide antibiotics
AU2002316550A1 (en) C12 modified erythromycin macrolides and ketolides having antibacterial activity
AU2001227702A1 (en) Osmotic device within an osmotic device
NO20012155L (en) New macrolide antibiotics
AU2003281694A1 (en) 6,11-4-carbon bridged ketolides
AU5037401A (en) Infinitely variable door arrester
CA2391834A1 (en) Macrolide antibiotics and treatment of pasteurellosis
AU2003218997A1 (en) Macrolides with antibacterial activity
AU2003247706A1 (en) 6, 11-4-carbon bridged erythromycin derivatives
AU2002345758A1 (en) Renewable, carbohydrate based co2-philes
ZA200107346B (en) Erythromycin derivatives.
ZA200305040B (en) Pharmaceutical compositions with antibiotic activity.
EP2371833A3 (en) 10-substituted macrolide antibiotics
AU2003297987A1 (en) High value split poly p-resistor with low standard deviation
AU6183700A (en) Erythromycin a derivatives
AU2002213267A1 (en) 6-o-substituted erythromycin derivatives having improved gastrointestinal tolerance
AU2001267179A1 (en) Variable ratio drive system
AU2002350538A1 (en) Sliding door device
AU2003285599A1 (en) Novel semisynthetic macrolide antibiotics of the azalide series
AU2002358628A1 (en) Synchronization device for gearboxes, in particular motor vehicle gearboxes
AU2002317415A1 (en) Azalide antibiotic compositions
AU2003263851A1 (en) Novel 11,12-Substituted Lactone Ketolide Derivatives Having Antibacterial Activity
AU2003304705A1 (en) 11-csubsituted erythromycin derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003290339

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2509419

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003782698

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 20038A69659

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2984/DELNP/2005

Country of ref document: IN

WWP Wipo information: published in national office

Ref document number: 2003782698

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006241060

Country of ref document: US

Ref document number: 10539759

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10539759

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: JP